Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities

NASHUA, N.H. – January 24, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company’s breast artificial intelligence (AI) platform was granted an Authorization to Ope... Continue reading

Dana Brown and Timothy Norris Irish offer extensive experience in technology, women’s breast health and unique global perspectives

NASHUA, N.H., January 11, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today it has appointed Dana Brown and Timothy Norris Irish as new independe... Continue reading

Company expects preliminary estimated Q4 2021 revenues to be between .8-.0 million

NASHUA, N.H., January 4, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the fourth quarter and full year of 2021. Based on preliminary, unaudited financial inf... Continue reading

Company’s President and incoming CEO to participate in a panel discussion titled “Med Tech / Digital Tools: What's the Mindset for 2022?” on January 5, 2022 at 2:00 pm ET

NASHUA, N.H., Dec. 23, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th, 2022.

Stacey Stevens, President and incoming CEO of iCAD, wil... Continue reading

Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor

Intriguing research supporting novel therapy approach recently published in peer-reviewed journal, Surgical Neurology International 

 ... Continue reading

Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor

Intriguing research supporting novel therapy approach recently published in peer-reviewed journal, Surgical Neurology International

Continue reading

NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimer’s Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).

Oppenheimer’s Imagine AI + Healthcare Investor Summit
Date:        Tuesday, December... Continue reading

Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain Chairman of iCAD Board

NASHUA, N.H. – December 6, 2021 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Board of Directors appointed Stacey Stevens as iCAD’s President and Chief Executive Off... Continue reading

Partnership will expand worldwide access to iCAD’s full suite of breast health solutions on Arterys’ fully cloud-based SaaS platform

SAN FRANCISCO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Arterys, the world's leading vendor-neutral AI platform, today announced it signed a global distribution agreement with iCAD, a global medical technology leader providing innovative cancer detection and therapy solutions. This partnership will expand access to iCA... Continue reading

World’s first FDA cleared AI breast cancer detection software to be highlighted in three scientific presentations at largest radiological meeting in the world

iCAD’s innovative breast health solutions, including ProFound AI Risk and PowerLook Density Assessment, to be showcased during the meeting

NASHUA, N.H. – November 29, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and th... Continue reading

NASHUA, N.H., Nov. 11, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 12th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 16, 2021, starting at 9:00 AM ET.

Management will be available to host virtual one-on-one meetings with investors who are registered to attend the conference. For more information, please visit Craig-Hallum.com.

About iCAD, Inc.
Headquartered in Nashua, N... Continue reading

Leading clinical and administrative experts to discuss how leveraging iCAD’s Breast Health Solutions and the Xoft System can enhance clinical efficiency and improve outcomes for patients

Webinar taking place on Thursday, November 18 from 3:00 to 4:30 PM ET

NASHUA, N.H. – November 11, 2021 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing... Continue reading

- Third Quarter Revenues of .4 Million Represented 20% Sequential Quarter Growth over the Second Quarter of 2021, Driven by 26% Growth in Detection Revenue and 10% Growth in Therapy Revenue -

- Third Quarter 2021 Revenues Represented 31% Growth Compared to the Third Quarter 2020 -

- Improving Enterprise Sales in the Third Quarter of 2021 Resulted in a 41% Sequential Quarter Increase in Detection Product Revenues -

-... Continue reading

NASHUA, N.H., Oct. 26, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Tuesday, November 9.

Tuesday, November 9th at 4:30pm ET

Domestic:

855-327-6837

... Continue reading

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

iCAD will unveil the latest generation of ProFound AI® f... Continue reading

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

NASHUA, N.H. and PARIS – October 7, 2021 - iCAD, Inc... Continue reading

Dense breasts can make it challenging to detect breast cancer during annual screenings, as overlapping tissue can hide or mimic breast cancer, even with digital breast tomosynthesis (DBT) exams. Breast density assessment has traditionally been determined by the radiologist’s visual assessment, but studies show that these can vary, and clinicians may even disagree with their own assessment year to year.[1] This can be confusing for patients, lead to unnecessary additional imaging, and increase patient and facility costs.

Continue reading

iCAD, Inc. recently launched ProFound AI® Risk for digital breast tomosynthesis (DBT), or 3D mammography, the world’s first commercially available clinical decision support tool that provides an accurate[1],[2] short-term breast cancer risk estimation that is truly personalized for each woman, based only on a 2D or 3D mammogram. The latest version of this software offers improved accuracy and enhanced functionality compared to previous versions.

“ProFound AI Risk has... Continue reading

Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening

Technology provides critical, risk-adaptive solutions for clinicians facing complex screening challenges presented by the COVID-19 pandemic

NASHUA, N.H. – September 29, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI® Risk for digital breast tomosynthesis... Continue reading

ImageCare Centers recently announced it will adopt ProFound AI® for Digital Breast Tomosynthesis (DBT) throughout all of ImageCare’s mammography centers this October as part of its “PINK Better Mammo” service. ProFound AI® was the first artificial intelligence (AI) software for DBT, or 3D mammography, to be FDA cleared; the software is clinically proven to improve accuracy and efficiency for radiologists reading mammography.[i]

Continue reading